Trial Profile
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SCALE; SCALE-Diabetes
- Sponsors Novo Nordisk
- 21 Jul 2019 This trial has been completed in United Kingdom as per the European Clinical Trials Database record.
- 01 Nov 2016 Results of population pharmacokinetic analysis in obese patients of this and other two trials published in the Clinical Pharmacokinetics
- 19 May 2016 Results of a post-hoc population pharmacokinetic analysis from SCALE-Diabetes and SCALE-Obesity and Pre-diabetes trials (n=2923) published in the Clinical Pharmacokinetics